市场调查报告书
商品编码
1496771
制酸剂市场:依药物类别、剂型、适应症、通路划分 - 全球预测 2024-2030Antacids Market by Drug Class (Acid Neutralizers, H2 Antagonist, Promotility Agents), Formulation (Liquid, Powder, Tablet), Indication, Distribution Channel - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年制酸剂市场规模为68.5亿美元,预计2024年将达72.4亿美元,2030年将达到101.8亿美元,复合年增长率为5.81%。
制酸剂是一种用于中和胃酸并缓解胃酸过多相关症状的药物。这包括胃灼热、消化不良和胃部不适等症状,这些症状可以透过增加胃部的 pH 平衡来缓解。制酸剂有多种形式出售,包括锭剂、液体和粉末,用于缓解与胃食道逆流 (GERD)、胃灼热和消化性溃疡相关的症状。全球胃食道逆流症 (GERD)、胃灼热和其他胃部疾病的盛行率不断增加,这增加了对制酸剂的需求。现代饮食和生活方式导致酸性消化不良和相关疾病的增加,进一步推动了对制酸剂的需求。旨在提高产品功效和减少副作用的持续研究和开发对市场成长有正面影响。然而,有关制酸剂核准和销售的严格规定可能会延迟产品上市并阻碍市场成长。替代疗法和酸相关疾病治疗的可用性对市场成长构成了重大挑战。此外,对天然和有机成分的研究正在取得进展,可以有效缓解缺氧及相关症状,为市场成长创造机会。提高抗酸产品功效和作用持续时间的药物传输技术创新正在进行中,为市场创造了成长潜力。
主要市场统计 | |
---|---|
基准年[2023] | 68.5亿美元 |
预测年份 [2024] | 72.4亿美元 |
预测年份 [2030] | 101.8亿美元 |
复合年增长率(%) | 5.81% |
区域洞察
美洲地区的制酸剂市场是由胃食道逆流(GERD)和压力性胃炎以及其他胃肠道疾病的高盛行率所推动的。在美国和加拿大等主要国家,消费者的偏好正趋向速效、调味和咀嚼产品。 EMEA(欧洲、中东和非洲)地区呈现多样化的格局,因为欧盟国家由于严格的监管而优先考虑基于医学证明的处方笺的治疗。欧洲、中东和非洲市场的特点是全球製药品牌众多,人们对具有其他健康益处(例如益生菌)的制酸剂越来越感兴趣。在文明病和自我治疗日益增长的推动下,中东和非洲的制酸剂市场正在扩大。此外,在亚太地区,中国和印度不断壮大的中阶以及不断增长的医疗保健支出正在推动制酸剂的广泛采用。由于日本人口老化以及对预防性医疗保健的日益重视,制酸剂的使用在亚太地区正在扩大。印度国内制酸剂市场的推动因素包括生活方式的改变、速食消费的增加以及人们对非处方药 (OTC) 认识的提高。
FPNV定位矩阵
FPNV 定位矩阵对于评估制酸剂市场供应商的市场定位至关重要。此矩阵提供了对供应商的全面评估,并检验了与业务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果,供应商被分为代表其成功程度的四个像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对制酸剂市场供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献,您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他重要指标。此外,该分析还提供了对该行业竞争性质的宝贵见解,包括在研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息,供应商可以做出更明智的决策并製定有效的策略,以在市场竞争中保持领先地位。
策略分析与建议
策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对目前在制酸剂市场中的地位进行全面评估,使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析,以确定核心优势和需要改进的领域。
[186 Pages Report] The Antacids Market size was estimated at USD 6.85 billion in 2023 and expected to reach USD 7.24 billion in 2024, at a CAGR 5.81% to reach USD 10.18 billion by 2030.
Antacid is a type of medication that is used to neutralize stomach acidity and alleviate symptoms associated with excess gastric acid. These include conditions such as heartburn, indigestion, and stomach upset, providing relief by increasing the pH balance in the stomach. The antacid products are available in various forms, including tablets, liquids, and powders to relieve symptoms associated with gastroesophageal reflux disease (GERD), heartburn, and peptic ulcers. The rising prevalence of GERD, heartburn, and other gastric ailments globally is driving the need for antacid products. Modern dietary habits and lifestyles contribute to increased incidences of acidity and related disorders, further propelling the demand for antacids. Continuous research and development aimed at enhancing product efficacy and reducing side effects positively impact market growth. However, stringent regulations regarding the approval and marketing of antacid products can delay product launches, hampering market growth. The availability of alternative therapies and treatments for acid-related disorders poses a significant challenge for market growth. Moreover, ongoing research into natural and organic ingredients can effectively relieve acidity and related conditions, creating opportunities for market growth. Ongoing innovation in drug delivery technologies to improve the efficacy and duration of action of antacid products, generating growth potential in the market.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 6.85 billion |
Estimated Year [2024] | USD 7.24 billion |
Forecast Year [2030] | USD 10.18 billion |
CAGR (%) | 5.81% |
Regional Insights
In the Americas region, the antacids market is driven by a high prevalence of gastroesophageal reflux disease (GERD) and stress-induced gastritis, amongst other digestive disorders. Consumer preferences lean toward fast-acting, flavored, and chewable forms in major countries such as the United States and Canada. The EMEA region presents a diverse landscape for antacids as the EU countries prioritize medically proven, prescription-based treatments due to stringent regulations. The EMEA market is characterized by a strong presence of global pharmaceutical brands and a growing interest in antacids that offer additional health benefits, such as probiotics. The antacids market in the Middle East and Africa is expanding, driven by lifestyle diseases and an increasing preference for self-medication. Moreover, in the APAC region, the burgeoning middle-class population and increased healthcare spending in China and India are expanding the adoption of antacids in the region. The rising aging population in Japan and a strong focus on preventive healthcare bolster the use of antacids in the APAC region. The domestic antacids market in India is propelled by lifestyle changes, increased fast food consumption, and rising awareness of over-the-counter (OTC) remedies.
Market Insights
The market dynamics represent an ever-changing landscape of the Antacids Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Antacids Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Antacids Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
TUMS Teams Up with DraftKings and Desus Nice to Launch TUMS Prop Bites, Allowing Big Game Fans to Go All In on Food for the First Time
TUMS partners with DraftKings to introduce an innovative platform, TUMS Prop Bites. This unique initiative creates awareness about making free food predictions by offering a chance to compare their selections with others nationwide. The brand's antacid tablets and chews are crafted to immediately relieve heartburn. These chewable solutions address symptoms such as heartburn, acid indigestion, sour stomach, and discomfort. [Published On: 2024-01-17]
Dexcel Pharma Acquires 8 OTC Brands to Strengthen its Consumer Healthcare Portfolio
Dexcel Pharma Ltd. announced its strategic acquisition of eight reputable over-the-counter (OTC) brands to diversify and strengthen its consumer healthcare offerings. The enhanced portfolio features well-known products such as EarCalm Spray, Sominex for sleep assistance, Wind-Eze as an antacid, Bisodol for indigestion relief, Cymex for cold sore treatment, Liberize for erectile dysfunction, Yeast Vite supplements, and MacKenzies Smelling Salts for catarrh and colds. [Published On: 2024-01-11]
Camber Pharmaceuticals Launches Generic Wellbutrin SR
Camber Pharmaceuticals expanded its product line by introducing Famotidine Powder for oral suspension, USP, a treatment developed to address various gastrointestinal conditions. Suitable for adults, this formulation effectively treats active duodenal and gastric ulcers, relieving the symptoms of non-erosive gastroesophageal reflux disease (GERD). [Published On: 2023-11-27]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Antacids Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Antacids Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Aero Healthcare AU Pty Ltd, Alcon Industries, Alkem Laboratories Ltd., Allegiant Health, AstraZeneca plc, Bayer AG, Biocon Limited, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Limited, Camber Pharmaceuticals, Inc., Cipla Limited, Daiichi Sankyo Company Limited, Dexcel Ltd., Dr. Reddy's Laboratories Ltd., GlaxoSmithKline PLC, Haleon PLC, Imerys S.A., J. B. Chemicals & Pharmaceuticals Limited, Johnson & Johnson Services, Inc., Magmit Pharmaceutical Co., Ltd., Mankind Pharma Ltd., Marksans Pharma, Nestle S.A., Novartis AG, Perrigo Company plc, Pfizer Inc., Raritan Pharmaceuticals, Inc., Reckitt Benckiser Group PLC, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Swiss Chem Healthcare by Swastik Lifesciences, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., The Procter & Gamble Company, Upsher-Smith Laboratories, LLC by Bora Pharmaceuticals, Wonderbelly, and Zoic Pharmaceuticals Pvt. Ltd..
Market Segmentation & Coverage